此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Mechanistic Study of Nicotinamide Riboside on NAD+ Biology in Individuals With Combined Pulmonary Hypertension

2026年4月28日 更新者:Evan Brittain、Vanderbilt University Medical Center

Pulmonary hypertension (PH) is a serious condition that puts strain on the heart and lungs and often leads to frequent hospital stays and shortened life expectancy. The most common cause is heart disease affecting the left side of the heart. A particularly high-risk form, called combined pre- and post-capillary pulmonary hypertension (CPH), occurs in about one in four people with heart failure. There are currently no approved treatments for CPH, and many patients develop right-sided heart failure and die earlier than expected.

This study is based on a new approach that uses advanced computer methods to analyze a patient's unique biology and identify potential drug targets. Using this method, we identified nicotinamide riboside (NR) as a promising option for people with CPH. NR is a form of vitamin B3 that helps the body make NAD⁺, a substance essential for how cells produce energy and stay healthy. NAD⁺ plays an important role in how heart and blood vessel cells function.

Previous research in animals suggests NR may help improve blood vessel changes in the lungs and support heart function. NR has also shown potential benefits in human studies related to cell energy, mitochondrial health, and reducing oxidative stress. In this study, NR is used only as a dietary supplement that supports normal body processes, not as a proven treatment.

The investigators will conduct a small, carefully controlled study in which participants receive NR and a placebo at different times. The goal is to understand how NR affects biological and biochemical markers in the body, not to test whether it improves symptoms or outcomes. Any clinical measurements are included only to help interpret the biological effects.

研究概览

研究类型

介入性

注册 (估计的)

10

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Tennessee
      • Nashville、Tennessee、美国、37203
        • 招聘中
        • Vanderbilt University Medical Center
        • 首席研究员:
          • Evan L Brittain, MD
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • Aged >/= 18 to 85 years of age
  • Diagnosis of Combined pre-/post-capillary PH (CPH) defined as mean pulmonary artery pressure >20mmHg, pulmonary capillary wedge pressure >15mmHg, and pulmonary vascular resistance ³3 Wood units
  • NYHA Class I - III
  • A qualifying Baseline RHC performed within 2 years of consent Clinical echocardiogram within the prior year with LVEF>/= 45%
  • Stable PH-specific and/or HF medication regimen and ≤1 diuretic adjustment within the three months prior to enrollment.
  • Ambulatory - able to perform the walk test

Exclusion Criteria:

  • Pulmonary hypertension due to congenital heart disease, connective tissue disease, or heritable pulmonary arterial hypertension
  • Prohibited from regular activity due to wheelchair bound status, bed-bound status, reliance on a cane/walker, activity-limiting angina, activity-limiting osteoarthritis, or other conditions that limit activity
  • Pregnancy
  • Drug and toxin-associated PAH patients with active drug use
  • Prior or active diagnosis of cirrhosis
  • Active Malignancy
  • Patients with evidence of moderate to severe hepatic impairment, defined as Child-Pugh Class B or C, or with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels greater than 3 times the upper limit of normal (ULN), should be excluded
  • eGFR by MDRD <30mL/mi
  • FEV1< 60% predicted with more than mild abnormalities on lung imaging Current enrollment in or completion of any other investigational product study within 30 days of Screening.
  • Hospitalization for any indication within 30 days of Day 1.
  • History of severe allergic or anaphylactic reaction or hypersensitivity to NR
  • No known mutation in NDUFB7

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:交叉作业
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
安慰剂比较:Placebo
Placebo portion of the trial
Participants will be randomized to receive either NR or a placebo for 6 weeks, followed by a 3-week washout period. After this, they will receive the alternate treatment for an additional 6 weeks.
有源比较器:Nicotinamide riboside (NR)
NR Portion of the trial
Participants will be randomized to receive either 1000mg NR Daily or a placebo for 6 weeks, followed by a 3-week washout period. After this, they will receive the alternate treatment for an additional 6 weeks.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Biochemical: Change in NADH:Ubiquinone Oxidoreductase Subunit B7
大体时间:Baseline, Week 6, Week 9, Week 15
Baseline, Week 6, Week 9, Week 15
Exploratory physiological measure: Change in 6-minute walk distance
大体时间:Baseline, Week 6, Week 9, Week 15
The 6MWT measures the distance (in meters), a participant can walk at a comfortable speed on a flat, hard surface in 6 minutes. The intent of the 6MWD test is to evaluate exercise capacity associated with carrying out daily physical activities.
Baseline, Week 6, Week 9, Week 15

次要结果测量

结果测量
措施说明
大体时间
Change in N-terminal pro-B-type natriuretic peptide Values
大体时间:Baseline, Week 6, Week 9, Week 15
Baseline, Week 6, Week 9, Week 15
Change in New York Heart Association Functional classification (NYHA)
大体时间:Baseline, Week 6, Week 9, Week 15
The New York Heart Association (NYHA) functional classification is a widely used system for assessing the severity of heart failure based on symptoms and their impact on physical activity. It is divided into four classes: Class I includes individuals with no limitations on physical activity and no symptoms during ordinary activities; Class II includes individuals with mild limitations on physical activity, where ordinary physical activity causes fatigue, shortness of breath, or other symptoms; Class III includes individuals with marked limitations on physical activity, where less-than-ordinary activity results in symptoms; and Class IV includes individuals who are unable to engage in any physical activity without discomfort and may experience symptoms even at rest. The NYHA functional class will be evaluated at Baseline and Visit 2. The NYHA functional classification is an ordinal scale ranging from Class I to Class IV, with lower class numbers indicating better functional status. Imp
Baseline, Week 6, Week 9, Week 15
Change in Empahsis-10 score
大体时间:Baseline, Week 6, Week 9, Week 15
The emPHasis-10 is a short and easy questionnaire that consists of 10 items that address breathlessness, fatigue, control, and confidence. Each item is scored on a semantic differential six-point scale (0-5), with contrasting adjectives at each end. A total emPHasis-10 score is derived using simple aggregation of the 10 items. emPHasis-10 scores range from 0 to 50, higher scores indicate worse quality of life
Baseline, Week 6, Week 9, Week 15
Change in SF-36 Score
大体时间:Baseline, Week 6, Week 9, Week 15
The SF36 includes one multi-item scale that assesses eight health concepts: 1) limitations in physical activities because of health problems; 2) limitations in social activities because of physical and emotional problems; 3) limitations in usual role activities because of physical health problems; 4) bodily pain; 5) general mental health (psychological distress and well-being); 6) limitations in usual role activities because of emotional problems; 7) vitality (energy and fatigue); and 8) general health perceptions. Remote subjects will complete the SF-36 at baseline and each subsequent visit during the study. Each SF-36 domain is scored using a standardized transformation to a 0-100 scale, with higher scores indicating better health status (i.e., fewer limitations, less pain, greater well-being, and higher vitality). Improvements over time are reflected by increases in domain scores relative to baseline.
Baseline, Week 6, Week 9, Week 15
Change in Minnesota Living with Heart Failure Questionnaire
大体时间:Baseline, Week 6, Week 9, Week 12
The MLHF (Minnesota Living with Heart Failure Questionnaire) is a widely used disease-specific instrument designed to assess the impact of heart failure on an individual's quality of life. The MLHF includes 21 items that evaluate various aspects of physical, emotional, and social functioning as affected by heart failure. It focuses on areas such as 1) physical limitations due to heart failure symptoms; 2) the emotional impact of living with heart failure; 3) interference with social activities; 4) effects on usual daily activities; and 5) overall quality of life as perceived by the patient. Participants will complete the MLHF at baseline and during each subsequent visit to monitor changes in their quality of life throughout the study. Each MLHF item is scored on a 6-point Likert scale ranging from 0 ("no impact") to 5 ("very much"), reflecting how much heart failure has affected the patient during the past month. Item scores are summed to produce a total score ranging from 0 to 105, w
Baseline, Week 6, Week 9, Week 12
Change in Tricuspid annular plane systolic excursion
大体时间:Baseline, Week 6, Week 9, Week 15
Baseline, Week 6, Week 9, Week 15
Change in RV Fractional Area
大体时间:Baseline, Week 6, Week 9, Week 15
Right ventricular fractional area change (RV FAC) is a non-invasive measure of right ventricular systolic function assessed using transthoracic echocardiography. RV FAC is calculated from standard echocardiographic images by comparing right ventricular area during diastole and systole. Higher RV FAC values indicate better right ventricular function. Change in RV FAC from baseline will be used to assess changes in right ventricular systolic performance during the study.
Baseline, Week 6, Week 9, Week 15
Change in RV Longitudinal Strain
大体时间:Baseline, Week 6, Week 9, Week 15
Right ventricular longitudinal strain is a non-invasive measure of right ventricular myocardial function assessed using transthoracic echocardiography with strain analysis. RV longitudinal strain quantifies myocardial deformation of the right ventricle during systole. More negative strain values indicate better right ventricular systolic function. Change in RV longitudinal strain from baseline will be used to assess changes in right ventricular myocardial performance during the study.
Baseline, Week 6, Week 9, Week 15
Incidence of Treatment-Emergent Adverse Event
大体时间:Baseline, Week 6, Week 9, Week 15
This will be a measure of adverse events in the study
Baseline, Week 6, Week 9, Week 15
Number of patients with an incidence of death
大体时间:Week 16
Week 16
Change in NAD+
大体时间:Baseline, 6-weeks, 9-weeks, 12-weeks
Baseline, 6-weeks, 9-weeks, 12-weeks
,Change in NADH.
大体时间:Baseline, 6-week, 9-week, 12-week
Baseline, 6-week, 9-week, 12-week
Change in Nicotinamide Mononucleotide
大体时间:Baseline, 6-week, 9 week, 15 week
Baseline, 6-week, 9 week, 15 week

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Evan L Brittain, MD、VUMC

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年4月9日

初级完成 (估计的)

2027年4月30日

研究完成 (估计的)

2027年7月30日

研究注册日期

首次提交

2026年4月22日

首先提交符合 QC 标准的

2026年4月28日

首次发布 (实际的)

2026年5月4日

研究记录更新

最后更新发布 (实际的)

2026年5月4日

上次提交的符合 QC 标准的更新

2026年4月28日

最后验证

2026年4月1日

更多信息

与本研究相关的术语

其他研究编号

  • 260020
  • R01HL163960 (美国 NIH 拨款/合同)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

We will provide a data dictionary/dataset available upon reasonable request as needed.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅